Clear All
12393 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
83831-0132-01 83831-0132 Pemetrexed AXTLE 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Jan 1, 2025 In Use
83831-0134-01 83831-0134 Leuprolide acetate LUTRATE DEPOT 22.5 mg/2ml Hormonal Therapy GnRH Agonist Intramuscular Mar 26, 2025 In Use
83831-0140-02 83831-0140 CARBOplatin KYXATA 20.0 mg/2mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Aug 11, 2025 In Use
83831-0141-08 83831-0141 CARBOplatin KYXATA 80.0 mg/8mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sep 10, 2025 In Use
83831-0142-50 83831-0142 CARBOplatin KYXATA 500.0 mg/50mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sep 10, 2025 In Use
83831-0143-01 83831-0143 Fluorouracil FAVLYXA 25.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Apr 1, 2026 In Use
83831-0144-05 83831-0144 Etoposide Avopef 100.0 mg/5mL Chemotherapy Plant Alkaloid Epipodophyllotoxins Intravenous Apr 1, 2026 In Use
83831-0147-05 83831-0147 Leucovorin calcium VYKOURA 50.0 mg/5mL Ancillary Therapy Chemoprotective Antidote Intramuscular, Intravenous Mar 16, 2026 In Use
83831-0148-35 83831-0148 Leucovorin calcium VYKOURA 350.0 mg/35mL Ancillary Therapy Chemoprotective Antidote Intramuscular, Intravenous Mar 16, 2026 In Use
83831-0149-50 83831-0149 Leucovorin calcium VYKOURA 500.0 mg/50mL Ancillary Therapy Chemoprotective Antidote Intramuscular, Intravenous Mar 16, 2026 In Use
83831-0183-04 83831-0183 Bendamustine hydrochloride BENDAMUSTINE HYDROCHLORIDE 100.0 mg/4mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous May 29, 2026 In Use
83858-0101-60 83858-0101 Dasatinib PHYRAGO 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug 1, 2024 In Use
83858-0102-60 83858-0102 Dasatinib PHYRAGO 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug 1, 2024 In Use
83858-0103-60 83858-0103 Dasatinib PHYRAGO 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug 1, 2024 In Use
83858-0104-30 83858-0104 Dasatinib PHYRAGO 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug 1, 2024 In Use
83858-0105-30 83858-0105 Dasatinib PHYRAGO 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug 1, 2024 In Use
83858-0106-30 83858-0106 Dasatinib PHYRAGO 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug 1, 2024 In Use
83980-0012-01 83980-0012 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 19, 2025 In Use
83980-0012-10 83980-0012 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 19, 2025 In Use
83980-0012-13 83980-0012 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 19, 2025 In Use
83980-0012-83 83980-0012 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 19, 2025 In Use
83980-0013-01 83980-0013 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 19, 2025 In Use
83980-0013-10 83980-0013 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 19, 2025 In Use
83980-0013-13 83980-0013 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 19, 2025 In Use
83980-0013-83 83980-0013 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 19, 2025 In Use

Found 12393 results — Export these results